Inhaled corticosteroids may have a place in treatment of COVID-19

The following conclusions were made for people with a confirmed diagnosis of COVID‐19 and mild disease:

Inhaled corticosteroids may result in little to no difference in all‐cause mortality in outpatients with mild COVID‐19 (low‐certainty evidence).

Inhaled corticosteroids probably reduce the risk of admission to hospital or death up to day 30 (moderate‐certainty evidence). Further, the intervention probably increases the resolution of all initial symptoms at day 14 (moderate‐certainty evidence) and may decrease the duration to symptom resolution (low‐certainty evidence).

Inhaled corticosteroids may result in little to no difference in the incidence of mild to moderate adverse events (low-certainty evidence). In terms of serious adverse events, the evidence is very uncertain (very‐low-certainty evidence).